Vasculitis in a patient with mevalonate kinase deficiency (MKD): a case report.

Pediatr Rheumatol Online J

Infection, Immunity and Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.

Published: November 2021

AI Article Synopsis

  • MKD is a rare autoinflammatory disease caused by mutations in the MVK gene, leading to various non-specific symptoms that can complicate diagnosis.
  • A 2-year-old boy with severe vasculitis symptoms was found to have MKD after genetic testing identified specific mutations, despite initial treatments not improving his condition.
  • This case underscores the importance of considering genetic testing for children with vasculitis to avoid delays in appropriate treatment.

Article Abstract

Background: Mevalonate kinase deficiency (MKD) is a rare autoinflammatory condition caused by biallelic loss-of-function (LOF) mutations in mevalonate kinase (MVK) gene encoding the enzyme mevalonate kinase. Patients with MKD display a variety of non-specific clinical manifestations, which can lead to diagnostic delay. We report the case of a child presenting with vasculitis that was found by genetic testing to be caused by MKD, and now add this autoinflammatory disease to the ever-expanding list of causes of monogenic vasculitides.

Case Presentation: A 2-year-old male presented with an acute 7-day history of high-grade fever, abdominal pain, diarrhoea, rectal bleeding and extensive purpuric and necrotic lesions, predominantly affecting the lower limbs. He had been suffering from recurrent episodes of fever from early in infancy, associated with maculopapular/petechial rashes triggered by intercurrent infection, and after vaccines. Extensive infection screen was negative. Skin biopsy revealed small vessel vasculitis. Visceral digital subtraction arteriography was normal. With a diagnosis of severe idiopathic cutaneous vasculitis, he was treated with corticosteroids and mycophenolate mofetil. Despite that his acute phase reactants remained elevated, fever persisted and the vasculitic lesions progressed. Next-generation sequencing revealed compound heterozygous mutation in MVK c.928G > A (p.V310M) and c.1129G > A (p.V377I) while reduced mevalonate enzyme activity was confirmed suggesting a diagnosis of MKD as a cause of the severe vasculitis. Prompt targeted treatment with IL-1 blockade was initiated preventing escalation to more toxic vasculitis therapies and reducing unnecessary exposure to cytotoxic treatment.

Conclusions: Our report highlights the broad clinical phenotype of MKD that includes severe cutaneous vasculitis and emphasizes the need to consider early genetic screening for young children presenting with vasculitis to exclude a monogenic vasculitis which may be amenable to targeted treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607720PMC
http://dx.doi.org/10.1186/s12969-021-00645-8DOI Listing

Publication Analysis

Top Keywords

mevalonate kinase
16
vasculitis
9
kinase deficiency
8
deficiency mkd
8
presenting vasculitis
8
cutaneous vasculitis
8
targeted treatment
8
mkd
6
mevalonate
5
vasculitis patient
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!